Background-Visceral adipose tissue (VAT) and other measures of central obesity predict incident atherosclerotic cardiovascular disease (ASCVD) events in middle-aged individuals, but these associations are less certain in older individuals age 70 years and older. Our objective was to estimate the associations of VAT and the android-gynoid fat mass ratio, another measure of central obesity, with incident ASCVD events among a large cohort of older men. Methods and Results-Two thousand eight hundred ninety-nine men (mean [SD] age 76.3 [5.5] years) enrolled in the Outcomes of Sleep Disorders in Older Men study had rigorous adjudication of incident ASCVD events (myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke). We used proportional hazards models to estimate the hazard ratios for incident ASCVD per SD increase of VAT or android-gynoid fat mass ratio (measured at baseline with dual-energy absorptiometry), adjusted for age, race, education, systolic blood pressure, smoking status, oxidized low-density lipoprotein level, treatment for hypertension, statin use, aspirin use, presence of diabetes mellitus, and study enrollment site. Over a mean (SD) follow-up period of 7.9 (3.4) years, 424 men (14.6%) had an incident ASCVD event. Neither VAT nor android-gynoid fat mass ratio were associated with incident ASCVD events, either unadjusted or after multivariable-adjustment (hazard ratios [95% confidence interval] per SD increase 1.02 [0.92-1.13] and 1.05 [0.95-1.17], respectively). Conclusions-Central adipose tissue, as measured by VAT or android-gynoid fat mass ratio, was not associated with incident ASCVD events in this study of older men.
Bibliographical noteFunding Information:
The Osteoporotic Fractures in Men (MrOS) Study is supported by the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research (grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128). This study was also supported by an unrestricted grant from Hologic, Inc.
Taylor, PhD, MPH reports grants from NIH outside the submitted work. Schwartz, PhD received an unrestricted grant from Hologic, Inc, to measure VAT on all MrOS participant whole body DXA scans. Lewis, MD, MSPH reports grants from NIH, during the conduct of the study and grants from Novo Nordisk outside the submitted work. The remaining authors have no disclosures to report.
- Android gynoid fat mass ratio
- Cardiovascular outcomes
- Central obesity
- Dual energy x-ray absorptiometry
- Visceral adipose tissue